Randomised Clinical Trial Investigating the Specificity of a Novel Skin Test (C-Tb) for Diagnosis of M. tuberculosis Infection

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Aggerbeck, Henrik ^a   Giemza, Rafaela ^c   Joshi, Paulatsya ^b   Tingskov, Pernille N ^a   Hoff, Søren T ^a   Boyle, Julia ^b   Andersen, Peter ^a   Lewis, David J M ^b,c  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; PHENOL; TUBERCULIN;

ADULT; AGED; ARTICLE; BCG VACCINATION; C TB SKIN TEST; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEMATOMA; HUMAN; IMMUNE RESPONSE; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INTERFERON GAMMA RELEASE ASSAY; LACTOCOCCUS LACTIS; MAJOR CLINICAL STUDY; MALE; NIGHT SWEAT; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PHENOL; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; VACCINATION; YOUNG ADULT;

EID: 84877763719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064215     Document Type: Article

References (24)

1. World Health Organization (2012) Global Tuberculosis Report. 1-272.
2. Comstock GW, Livesay VT, Woolpert SF, (1974) The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 99: 131-138.
3. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, et al. (2004) The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 8: 278-285.
4. Abubakar I, Griffiths C, Ormerod P, (2012) Diagnosis of active and latent tuberculosis: summary of NICE guidance. BMJ 345: e6828.
5. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495-1505 S0140-6736(11)60438-8 [pii];10.1016/S0140-6736(11)60438-8 [doi].
6. World Health Organization (2006) Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO/HTM/TB/2006 371: 1-41.
7. Shingadia D, Novelli V, (2003) Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis 3: 624-632.
8. Denkinger CM, Dheda K, Pai M, (2011) Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 17: 806-814 10.1111/j.1469-0691.2011.03555.x [doi].
9. Pai M, Riley LW, Colford JM Jr, (2004) Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4: 761-776.
10. Mantoux C, (1908) Intradermo-réaction de la tuberculine. Compt Rend Acad Sci 147: 355-357.
11. Snider DE Jr, (1982) The tuberculin skin test. Am Rev Respir Dis 125: 108-118.
12. Gallant CJ, Cobat A, Simkin L, Black GF, Stanley K, et al. (2010) Tuberculin skin test and in vitro assays provide complementary measures of antimycobacterial immunity in children and adolescents. Chest 137: 1071-1077.
13. Huebner RE, Schein MF, Bass JB Jr, (1993) The tuberculin skin test. Clin Infect Dis 17: 968-75.
14. Poulsen A, (1954) Some clinical features of tuberculosis. Acta Tuberc Scand 24: 311-346.
15. Department of Health (2004) Diagnosis of Tuberculosis. In: The South African National Tuberculosis Control Programme. Practical Guidelines. 45-53.
16. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, et al. (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37: 88-99 09031936.00115110 [pii];10.1183/09031936.00115110 [doi].
17. World Health Organization (2011) Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. Policy Statement. 1-61.
18. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R, (2007) T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 7: 428-438.
19. Aggerbeck H, Madsen SM, (2006) Safety of ESAT-6. Tuberculosis (Edinb) 86: 363-373.
20. Bergstedt W, Tingskov PN, Thierry-Carstensen B, Hoff ST, Aggerbeck H, et al. (2010) First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. PLoS ONE 5: e11277 10.1371/journal.pone.0011277 [doi].
21. Arend SM, Franken WP, Aggerbeck H, Prins C, van Dissel JT, et al. (2008) Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis (Edinb) 88: 249-261.
22. van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P, (2000) Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 7: 155-60.
23. Menzies D, Pai M, Comstock G, (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146: 340-354.
24. Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, et al. (2010) High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. J Infect Dis 201: 15-19 10.1086/648611 [doi].